New Zealand Society of Anaesthetists (NZSA) – Level 1, Central House, 26 Brandon Street, Wellington 6011
04 494 0124 | nzsa@anaesthesia.nz

Ora Taiao – Environmental sustainability and health
Ora Taiao (the NZ Climate and Health Council), which comprises of health professionals, is focused on addressing the negative impacts of climate change on health, and the health gains that are possible through strong, health-centred climate action. The NZSA recently met with Ora Taiao representatives to look at how we can support projects of common interest.

Ora Taiao has written an open letter which calls on the Ministry of Health to set greenhouse gas emission (GHG) targets for DHBs, in line with commitments under the Paris Agreement. NZSA member and Ora Taiao member Dr Matt Jenks says that they hope to present the open letter to the Ministers of Climate Change and Health by the middle of the year. You can read and sign the letter here. Find out more about Ora Taiao’s work on their website.

World Federation of Societies of Anaesthesiologists
The NZSA has strong global connections, which includes our membership and support of the WFSA. Their Highlights 2017 Report provides an overview of key achievements.

Bullying of senior doctors rife in public health system, report finds

A survey published of senior doctors and dentists working in New Zealand’s public health system found more than a third had been bullied at work, and two-thirds had witnessed others being bullied. The Association of Salaried Medical Specialists (ASMS) report, Bullying in the New Zealand senior medical workforce: prevalence, correlates and consequences, is available on the ASMS website at https://www.asms.org.nz/wp-content/uploads/2017/11/ASMS-Health-Dialogue-Bullying-WEB.pdf.

Key findings included:

  • More than a third of respondents (37.2%) said they had been bullied, and more than two-thirds (67.5%) reported witnessing bullying of colleagues.
  • The prevalence of bullying in New Zealand’s senior doctors appears higher than shown in comparable international surveys of health sector workers.
  • Bullying is strongly associated with high workplace demands, and low peer and non-clinical managerial support.
  • Workplace bullying occurs more often, and in different forms, for certain groups of senior doctors, eg overseas-trained doctors working in New Zealand, women, doctors aged 40 to 59, and in some specialties (emergency medicine, general surgery and specialist surgery).
  • Only a third of doctors who said they had been bullied reported what had happened, with the main reasons for not reporting being fear of not being supported, and concern that reporting would make the situation worse.

Decision to delist tramadol hydrochloride oral drops 100 mg per ml
The NZSA welcomes PHARMAC’s decision to progress the proposal to delist tramadol hydrochloride oral drops 100 mg per ml from Part II of Section H of the Pharmaceutical Schedule, and instead list a 10 mg per ml strength of tramadol hydrochloride oral solution for use in DHB hospitals. This was the subject of a consultation letter dated 4 October 2016. In summary, the effect of the decision is that:
– tramadol hydrochloride oral solution 10 mg per ml was listed for use in DHB
hospitals from 1 January 2017.
– tramadol hydrochloride oral drops 100 mg per ml were delisted from 30 June 2017.

Sole supply of propofol
Sole Supply Contracts (Hospital Supply Status) have been awarded to two suppliers for propofol:
• AFT Pharmaceuticals’  Provive brand MCT-LCT 1% inj 10 mg per ml, 20 ml vial;
• Fresenius Kabi (NZ)’s Fresofol brand 1% MCT/LCT inj 10 mg per ml, 50 ml vial and inj 10 mg per ml, 100 ml vial.

These products will be the only brands of propofol that can be used in DHB hospitals from 1 June 2016 until 30 June 2019. The 50ml and 100ml vials of Fresofol were introduced on 1 April. All other presentations of propofol currently listed were delisted from 1 June 2016. The NZSA wrote a submission to Pharmac earlier in the year expressing strong support for continued availability of Provive and Fresofol and said consistency of supply for NZ’s leading anaesthetic drug is essential.

[/vc_column_text][/vc_column][/vc_row]